Literature DB >> 6432383

Human mononuclear phagocytes from different anatomical sites differ in their capacity to metabolize arachidonic acid.

E Vicenzi, A Biondi, C Bordignon, A Rambaldi, M B Donati, A Mantovani.   

Abstract

Human mononuclear phagocytes have the capacity to metabolize arachidonic acid (AA) into prostaglandins (PG) endowed with potent activities in immune responses and inflammatory processes. We have evaluated AA metabolism in human mononuclear phagocytes harvested from different anatomical sites (blood monocytes, macrophages from milk, peritoneal cavity and alveolar spaces). At thin layer radiochromatography, the AA metabolites mainly present were PGE2, TxB2 and, only in bronchoalveolar macrophages, a peak comigrating with PGD2. No appreciable levels of 6-keto-PGF1 alpha were observed. These data were confirmed using specific radioimmunoassays for TxB2, PGE2 and 6-keto-PGF1 alpha. Blood monocytes and bronchoalveolar macrophages were the poorest producers of PG, with the possible exception of PGD2 in bronchoalveolar macrophages. The high amounts of TxB2 and PGE2 produced by milk macrophages could contribute to the levels of PG in human milk. Thus, human mononuclear phagocytes obtained from diverse anatomical sites are considerably heterogeneous in terms of AA metabolism.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6432383      PMCID: PMC1536136     

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  30 in total

1.  Inhibition of gastric secretion by prostaglandins.

Authors:  A Robert; J E Nezamis; J P Phillips
Journal:  Am J Dig Dis       Date:  1967-10

2.  Macrophages synthesis and release prostaglandins in response to inflammatory stimuli.

Authors:  J L Humes; R J Bonney; L Pelus; M E Dahlgren; S J Sadowski; F A Kuehl; P Davies
Journal:  Nature       Date:  1977-09-08       Impact factor: 49.962

3.  Regulation of human natural killing. I. The role of monocytes, interferon, and prostaglandins.

Authors:  H S Koren; S J Anderson; D G Fischer; C S Copeland; P J Jensen
Journal:  J Immunol       Date:  1981-11       Impact factor: 5.422

4.  Inhibition of natural killer activity by human bronchoalveolar macrophages.

Authors:  C Bordignon; F Villa; P Allavena; M Introna; A Biondi; R Avallone; A Mantovani
Journal:  J Immunol       Date:  1982-08       Impact factor: 5.422

Review 5.  Prostaglandins, prostacyclin, and thromboxanes.

Authors:  J C McGiff
Journal:  Annu Rev Pharmacol Toxicol       Date:  1981       Impact factor: 13.820

6.  Effect of prostaglandin E2 on esophageal motility in man.

Authors:  A Mukhopadhyay; S Rattan; R K Goyal
Journal:  J Appl Physiol       Date:  1975-09       Impact factor: 3.531

7.  Antibody-dependent and -independent cytotoxicity of human mononuclear phagocytes: defective stimulation of tumoricidal activity in milk macrophages.

Authors:  A Biondi; G Peri; N Colombo; G Bolis; A Mantovani
Journal:  Clin Exp Immunol       Date:  1982-09       Impact factor: 4.330

8.  Release of prostaglandin by mitogen- and antigen-stimulated leukocytes in culture.

Authors:  V A Ferraris; F R DeRubertis
Journal:  J Clin Invest       Date:  1974-08       Impact factor: 14.808

9.  Prostaglandin D2 generation after activation of rat and human mast cells with anti-IgE.

Authors:  R A Lewis; N A Soter; P T Diamond; K F Austen; J A Oates; L J Roberts
Journal:  J Immunol       Date:  1982-10       Impact factor: 5.422

10.  Distribution of prostaglandin biosynthetic pathways in several rat tissues. Formation of 6-ketoprostaglandin F1alpha.

Authors:  C R Pace-Asciak; G Rangaraj
Journal:  Biochim Biophys Acta       Date:  1977-03-25
View more
  2 in total

1.  Enhanced capacity for release of leucotriene B4 by neutrophils in rheumatoid arthritis.

Authors:  J Elmgreen; O H Nielsen; I Ahnfelt-Rønne
Journal:  Ann Rheum Dis       Date:  1987-07       Impact factor: 19.103

2.  Tannin mediated alveolar macrophage protein phosphorylation.

Authors:  S L Hempel; M S Rohrbach
Journal:  Mol Cell Biochem       Date:  1989-04-11       Impact factor: 3.396

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.